July 20, 2017 1:18 PM ET

Life Sciences Tools and Services

Company Overview of Absorption Systems, LP

Company Overview

Absorption Systems, LP operates as a preclinical contract research organization. The company assists pharmaceutical, biotechnology, and medical device companies in identifying and overcoming absorption, distribution, metabolism, excretion, and toxicity barriers in the development of drugs, biologics, and medical devices. It offers preclinical services comprising predesigned and customizable assays and studies, which include lead optimization, NDA-enabling and IND-enabling, and bioanalysis services. The company also provides preclinical formulation profiling and characterization of biologics focusing on polypeptides, recombinant proteins, monoclonal antibodies, protein conjugates, nucleic aci...

436 Creamery Way

Suite 600

Exton, PA 19341

United States

Founded in 1996





Key Executives for Absorption Systems, LP

Co-Founder, Chief Executive Officer and President
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer
Vice President of Scientific and Corporate Communications
Compensation as of Fiscal Year 2017.

Absorption Systems, LP Key Developments

Absorption Systems Licenses Cell Line to Pfizer

Absorption Systems announced a technology licensing agreement with Pfizer Inc. The core technology is a human cell line engineered to express an individual drug transport protein, designed to test for potential safety issues early in the drug development process. The cell line is stably transfected with the human SLCO1B1 gene, which codes for a protein known as organic anion transporting polypeptide (OATP) 1B1. Drug transporters such as OATP1B1 have received attention from drug regulatory bodies such as the U.S.  Food and Drug Administration (FDA) and the European Medicines Agency (EMA) because of their importance in drug absorption, efficacy, elimination, and safety.  Only in recent years have scientists come to appreciate the importance of transporters and their genetic variants in different individuals. Test systems such as the OATP1B1-transfected cells have led to a better understanding of the roles that drug transporters play in overall drug disposition, and make it possible to predict potentially dangerous drug-drug interactions long before a new drug is administered to people. This human OATP1B1 assay system will enable Pfizer to test potential new drug candidates for interactions with OATP1B1, which plays a central role in the effectiveness, safety, and drug-drug interactions of many drugs, including the widely used statins. Drug candidates that are substrates or inhibitors of OATP1B1 may look promising in early-stage testing but have safety issues once they get into clinical trials or post-approval, which is why the FDA and EMA now require lab-based testing for such interactions. The Absorption Systems cell line expresses OATP1B1 at a high level and allows users to predict human outcomes during preclinical testing.

Biogen Inc. Renews License with Absorption Systems for Testing Platform

Absorption Systems announced the renewal of a technology licensing deal with Biogen. After years of contract testing by Absorption Systems using MDR1-MDCK cells, Biogen licensed the technology associated with the test system from Absorption Systems in October 2015 and is renewing the license for another year. This cell line is stably transfected with the human MDR1 gene, which codes for a protein known as multi-drug resistance protein or P-glycoprotein (P-gp). Drug transporters such as P-gp have received increasing attention from drug regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) because of their importance in drug absorption, excretion, and safety. This human MDR1 assay system enables Biogen to test new drug candidates for interactions with P-gp, which is involved in resistance of tumors to anticancer drugs, drug distribution and clearance, and drug-drug interactions (DDIs). As a result of P-gp, drugs that show promising efficacy in the lab may be inaccessible to the organ of interest during clinical trials. MDR1-MDCK cells express P-gp at a high level and allow users to predict human outcomes during early-stage preclinical testing of their drug candidates.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Absorption Systems, LP, please visit www.absorption.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.